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The natural occurrence of palladium (Pd) is rare. It is obtained as a by-product during
the extraction ofplatinum and, until the present time, its uses were small in number-prin-
cipally in the manufacture ofjewelry, dental alloys, chemical catalysts, and electrical con-
tacts. Interest in Pd toxicology has been limited to occupational exposures and even that
has been sparse. Recently Pd has been chosen as one ofthe metals to be incorporated into
the automotive catalytic converter material.
Palladium chloride has been shown to be extremely toxic when given to rabbits in-
travenously. Animals rapidly injected quickly died with damage chiefly to the heart. This
heart damage was not explained or further defined, and other references addressing this
subject have not been found. The objective of our study was to investigate and attempt to
characterize toxic actions of soluble Pd compounds on the cardiovascular system of the
unanesthetized rat. Surgically prepared rats were monitored for ECG, aortic blood
pressure, cardiac contractility (dp/dt), and respiration before, during, and 1 hr following in-
travenous injections ofPd2+ salt solutions.
Our findings indicate that injected Pd2+ profoundly disturbs the electrical integrity of
ventricular myocardium. Effective doses induce cardiac arrhythmias with the consequen-
tial fall in blood pressure; the extent of the response is dose related.
An immediate cardiovascular effect is seen when doses of0.4 mg/kg or more ofPd ion as
PdSO4 is administered over a 40-sec period of time via the femoral vein. Pd(NOS)2 and
PdCls appear to have similar activity. To achieve an equal responsethree times as much Pd
is necessary as (NH4)SPdCI4 or K2PdCl4.
Introduction
Palladium (Pd), discovered by Wollaston in
1803, entered industry as a useful metal in 1919 (1).
It occurs in association with platinum and is
recovered as a by-product in the extraction of
platinum from the residues of copper and nickel
refineries. Previously Pd was used in limited quan-
tities, principally for the manufacture of electrical
contacts, dental alloys, chemical catalysts, and
jewelry (2). Toxicological information concerning
the metal is meager and there is no known report
on human toxicity from industrial exposure. Cur-
rently there has been interest generated in health
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effects of Pd because of its use in the automotive
catalytic converter.
It has been used for humans therapeutically, but
ineffectively, for tuberculosis, gout, obesity, and as
a skin germicide. Pd(OH)2 injected subcutaneously,
5-7 mg/day for 3 months, as a remedy for obesity,
resulted in weight loss and fever (2). A buffered
PdCl2 solution of 1 mg/ml, when applied as a patch
test, did not cause skin irritation after 24 hr (1).
The few studies carried out on animals have shown
that subcutaneous injections into rabbits (3) and
rats (4-24 mg/kg body weight) (1) caused no ill
effects. Schroeder and Mitchener (4) fed mice
PdCl2 in their drinking water (5 ppm) from birth to
death. This compound appeared to enhance the in-
cidence oftumors but showed little cellular toxicity
in terms of weight gain. Orestano (3) found that
18.6 mg/kg of PdCl2, when given intravenously in
December 1975 41small doses to rabbits, would prove fatal after 12
days with damage to kidney, bone marrow, and
liver, but if given rapidly, 0.6 mg/kg caused death
with damage chiefly to the heart. Meek (1) found
that 0.5-1.7 mg/kg given intravenously to rabbits
resulted in loss of appetite with reduced urine and
feces output. The animal which received 1.7 mg/kg
died after 17 days.
The objective of the present study was to in-
vestigate and attempt to characterize toxic actions
of palladium compounds on the cardiovascular
system of the unanesthetized rat. Intravenous in-
jections of PdSO4, PdCl2, Pd(NO3)2, (NH4)2PdCl4,
and K2PdCl4 were studied.
Methods
Male Sprague-Dawley rats (300 ± 50 g) were
surgically prepared 1 day prior to use. Surgery con-
sisted ofinserting polyethylene tubing (PE 50) into
the abdominal aorta and (PE 10) into the femoral
vein. Both catheters were guided through sub-
cutaneous tissue and exteriorized at the back ofthe
neck via a puncture would through the skin. The
aortic catheter was used for measurement ofblood
pressure and the venous catheter for injection of
test solution. Six small silver electrodes, fitted with
micro-strip connector pins, were inserted under the
skin and sutured. These electrodes were arranged
laterally so that four were near the limbs to record
the ECG (lead 1) and two were arranged on the
lateral surface of the rib cage for respiratory
FIGURE 1. Block diagram of recording system. Pressure
transducer for measurement of arterial blood pressure,
calibrated with a Hg manometer (Miller Instruments);
differentiator for a record ofmaximum rate ofchange of aor-
tic pressure, time constant of 1 msec, calibrated with an
oscilloscope; impedance pneumograph for record of rate and
relative depth of respiration (Narco Bio-Systems); ECG
preamplifier (Grass); polygraph: (Grass 7C).
measurements. Following surgery, animals were
returned to their cages and given food and waterad
libitum (Purina Lab Chow and tap water). For test-
ing, the animals were placed in a tubular plastic
holder and sensor leads were connected to the
recorder. Details of the measurement system are
seen in Figure 1. Rats were monitored for a 30-min
control period, injected, and then monitored for the
next 60 min.
Palladium compounds were dissolved in water
and diluted in saline just before the injection. The
Pd concentration of solutions were determined by
atomic absorption with the use ofa heated graphite
atomizer. Analysis were repeated a number of
times on each solution throughout its period ofuse.
The total injection volume was 0.5 ml, and it was
infused over a 40-sec period of time. The fitness of
venous catheter was varified at the end ofeach ex-
periment by introducing a lethal dose of sodium
pentobarbital through it and monitoring the
response.
Twelve control animals were injected with
saline. PdSO4 was the major compound studied; 41
rats were administered doses ranging from 0.25-2
mg/kg of the palladium ion. Once the toxicity pat-
tern for this salt was established, dose levels for the
remaining compounds were efficiently selected.
Ninerats weredosed withPd(NO3)2,six with PdCl2,
21 with (NH4)2PdCl4, and eight with K2PdCl4.
Figure 2 shows a typical polygraph recording
from -a control period. This tye of regularity, i.e.,
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IFIGUR'E 2. Typical control-period polygraph recording from
the unanesthetized rat.
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quired for the animal to be used as a test subject.
Control period values for all animals used in the
study were: systolic blood pressure, 145 + 17;
diastolic blood pressure, 104 ± 16; breathing rate,
127 + 27; and heart rate, 443 + 39. The ECG pat-
tern, breathing amplitude, and dp/dt were
measured for relative changes before and after the
injection. No changes were noted in saline-injected
animals.
Results and Comments
Intravenously injected PdSO4, Pd(NOs)2, PdCl2,
(NH4)2PdCl4, and K2PdCl4 solutions exerted im-
mediate cardiovascular actions in the unanesthe-
tized rat. The mostconstant pharmacological effect
seen was the rapid induction of ventricular ar-
rhythmias. Other alterations appeared to be depen-
dent upon the severity ofthis event. In toxic doses,
a premature ventricular contraction, followed by a
compensatory pause, did not usually influence the
blood pressure significantly; however, ventricular
tachycardia or ventricular contractions originating
from multiple foci often progressed into ventricular
fibrillation terminating in death of the animal.
Ventricular arrhythmias were not preceded by any
obvious change in blood pressure. ECG pattern, or
FIGURE 3. Recording of a mild toxic event following an in-
travenous injection of 0.5 mg/kg of Pd in as PdSO4. Blood
pressure values dropped during the ECG irregularities but
recovered once a normal depolarization pattern resumed.
Breathing was not affected.
breathing. Records following mild toxic doses were
found to be in normal limits with the exception of
an occasional premature ventricular contraction.
Figure 3 shows a tracing of the occurrence of ar-
rhythmias following an injection of PdSO4; Figure
4 is a record ofevents subsequentto a lethal dose of
PdCl2. Effects from injected palladium compounds
were rated (Table 1) as to their capability for pro-
ducing changes in the ECG and or hemodynamics
of the unanesthetized rat. Effects were plotted
against the total dose of palladium ion for each
compound (Fig. 5).
When the assigned effects values were plotted
against dose, the distribution of these points could
be fitted to a series of S-shaped curves (Fig. 5).
PdSO4, Pd(NO3)2, and PdCl2appearedto havesimi-
lar pharmacological activity, where as the complex
divalentcompounds(NH4)2PdCl4andK2PdCl4were
comparable to each other but less potent than the
simple palladium salts. A mean dose of
palladium, causing mild effects was 0.4 ± 0.2
mg/kg, when administered as PdSO4, and 1.2 + 0.3
mg/kg as (NH4)2PdC14; severe effects were seen at
FIGURE 4. Lethal effects of an intravenous injection of 1.0
mg/kg of Pd ion as PdCl2. Numerous preventricular contrac-
tions followed the injection, resulting in a precipitous fall in
blood pressure.
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43Table 1. Rating system used for palladium compounds.
Number
Assigned Effect
0 No changes from control values in the ECG, blood
pressure, dp/dt or breathing for 60 min following
the injection
1 Cardiac arrhythmias without a consequential fall
in blood pressure or a measurable change in the
ECG (most often seen as occasional ventricular
premature contractions); blood pressure, dp!dt,
and breathing maintained at control values for 60
min following the injection
2 Occurrence of multiple forms of arrhythmias with
concomitant decreases in blood pressure; life-
threatening situation for a period of time;
however, the animals survived for 60 min follow-
ing the injection
Abnormal ECG patterns and blood pressure read-
ings greater than control values were frequent
residual consequences
3 Death of the animal
Usually ECG evidence of ventricular tachycardia,
with impulses often originating from more than
one focus and terminating in ventricular fibrilla-
tion until hypoxia developed
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FIGURE 5. Effects of intravenously injected palladium on the
unanesthetized rat (none, mild, severe, death effects;
described in the text). Comparison of five different water
soluble compounds. PdSO4 and (NH4)2PdCl4 are signifi-
cantly different; p < 0.005.
levels of 0.06 ± 0.1 and 1.7 (one animal) mg/kg,
respectively. Responses to the two compounds were
significantly different (p < 0.005).
To summarize, the commercial use ofpalladium
is expanding rapidly, possible due to the innovation
so-
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FIGURE 6. Palladium used in the United States from both
domestic and foreign mine sources. The 1940 point was
taken from Meek (1), whereas the remainder ofthe informa-
tion was supplied by the U.S. Bureau of Mines, Division of
Non-Ferrous Metals.
ofthe automotive catalytic converter (Fig. 6). Thus,
it has become important to clarify .its phar-
macologic actions and or toxic properties. In the
past little effort has been spent on the toxicology of
palladium compounds. Two separate studies have
shown rapid death following intravenous injections
of PdCl2 (1, 3). Although damage to the heart was
indicated (3), the mechanisms underlying the
effects were poorly understood and no general
assumptions were made by the investigator. The
present study has indicated that number of water-
soluble palladium salts will quickly disrupt the
electrical integrity of the ventricular myocardium
of the unanesthetized rat. The palladium divalent
ion when tested as a simple salt [PdSO4, Pd(NO3)2,
or PdCl2] appeared to have three times the potency
than when tested as a more complex compound
(NH4)2PdCl4 or K2PdCl4.
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